Jounce Therapeutics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference

Rhea-AI Summary

Jounce Therapeutics, Inc. (NASDAQ: JNCE) will participate in a fireside chat at the Raymond James Human Health Innovation Conference on June 17, 2020, at 3:00 p.m. ET. This event will focus on the company's innovative cancer immunotherapies and predictive biomarkers. Interested parties can access a live webcast on Jounce's website under the 'Events and Presentations' section, with a replay available for 30 days post-event. Jounce continues to develop its clinical-stage programs, including vopratelimab and JTX-4014, aimed at enhancing cancer treatment.

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020 at 3:00 p.m. ET.

A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TIS^vopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment. For more information, please visit www.jouncetx.com.

Investor and Media Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
kjoshi@jouncetx.com

FAQ

What is Jounce Therapeutics presenting at the Raymond James Conference on June 17, 2020?

Jounce Therapeutics will discuss its cancer immunotherapy developments and predictive biomarkers during a fireside chat.

Where can I watch the Jounce Therapeutics presentation from the conference?

The presentation can be streamed live on Jounce's website in the 'Events and Presentations' section.

What are the main products being developed by Jounce Therapeutics?

Jounce is developing vopratelimab, a monoclonal antibody, and JTX-4014, a PD-1 inhibitor, among other programs.

How long will the webcast of Jounce Therapeutics' presentation be available?

The webcast will be archived for 30 days following the presentation.

What stage are Jounce Therapeutics' clinical programs in as of June 2020?

Jounce has two clinical-stage programs: vopratelimab in a Phase 2 trial and JTX-4014 for combination use.